"Inclisiran: Early LDL-C target achievement in a real-life population".

ABSTRACT:

Background and objectives

Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with atherosclerotic cardiovascular diseases. Inclisiran, a small interfering RNA, has been observed to effectively and sustainably reduce LDL-C in large randomized controlled trials (RCTs); however, real-world data on its short-term efficacy and use are limited. This study aims to assess the efficacy and safety of inclisiran in a real-life population within one month from the first administration.

Methods

This observational, single-center, retrospective cohort study included patients affected by dyslipidemia who could not achieve their LDL-C target despite a maximum tolerated oral lipid-lowering therapy (LLT). 284 mg Inclisiran was subcutaneously administered. Blood samples

SUBMITTER: Briani F 

PROVIDER: S-EPMC11848444 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature